Compare XBIT & TTEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | TTEC |
|---|---|---|
| Founded | 2005 | 1982 |
| Country | United States | United States |
| Employees | N/A | 69400 |
| Industry | Pharmaceuticals and Biotechnology | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.8M | 67.0M |
| IPO Year | 2015 | 1996 |
| Metric | XBIT | TTEC |
|---|---|---|
| Price | $1.88 | $1.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 92.8K | ★ 347.8K |
| Earning Date | 11-20-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.80 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,509,171,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $30.47 | $0.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.15 |
| 52 Week Low | $1.80 | $1.18 |
| 52 Week High | $3.44 | $3.99 |
| Indicator | XBIT | TTEC |
|---|---|---|
| Relative Strength Index (RSI) | 39.12 | 41.77 |
| Support Level | $1.80 | $1.19 |
| Resistance Level | $2.42 | $1.50 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 27.27 | 6.56 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
TTEC Holdings Inc provides customer engagement management tools and services. The company operates through two operating segment, TTEC Digital and TTEC Engage. TTEC Digital is engaged in building and implementing cloud-based and on-premises customer experience tools that enable clients to develop customer engagement strategies. TTEC Engage focuses on delivering sales and marketing solutions to help clients boost their revenue as well as on managing customer's front-to-back office processes to optimize the customer experience. TTEC Engage contributes the vast majority of the company's revenue, and its revenues are derived from the United States and Canada, followed by Philippines, Asia-Pacific and India.